arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Tyra Biosciences, Inc.

TYRA

$23.21 ▼ -2.34 (-9.16%) at close

7 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Tyra Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.4B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -40.5% ↘

FCF / Share $-1.60 ↘

Trailing P/E —

Price / Book 4.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-119.95M

↓ -38.7% —

FCF / Share Free cash flow per share

$-1.60

↓ -29.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	-33.1% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	6.8% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-22.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	30.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-38.7% Weak ↑ Weak Improving Year-over-year change in net income	-25.1% Weak ↑ Weak Improving Year-over-year change in net income	-25.0% Weak ↑ Weak Improving Year-over-year change in net income	-110.4% Weak Weak Year-over-year change in net income	-181.6% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-29.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	-3.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	1.8% Caution Caution Year-over-year change in free cash flow	31.5% Excellent Excellent Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	0.79x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-40.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-24.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-30.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-18.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-6.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	53.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-47.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-28.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-35.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-22.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-8.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	-58.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-46.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-409%)	-25.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-268%)	-33.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-326%)	-21.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-243%)	-8.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-158%)	68.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+356%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	—	—	—	—	-9297.00x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-77.39M	$-91.97M	$-58.01M	$-251.21M	$-302.18M	$-15.22M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-2.01	$-1.51	$-1.62	$-1.32	$-1.91	—	—
Free Cash Flow per Share (USD)	$-1.60	$-1.23	$-1.19	$-1.21	$-1.77	—	—
Book Value per Share (USD)	$4.83	$6.76	$4.75	$6.09	$7.28	$-7.45	—
Tangible Book Value per Share (USD)	$4.83	$6.76	$4.75	$6.09	$7.28	$-7.45	—
Basic Weighted Avg Shares (shares)	59.60M	57.22M	42.70M	41.88M	13.78M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$247.36M	$332.87M	$196.34M	$251.59M	$300.44M	$13.42M	—
Total Equity (USD)	$259.18M	$343.15M	$204.26M	$257.83M	$301.74M	$-13.64M	$-4.74M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$546.00K	$519.00K	$357.00K	$296.00K	$140.00K	$47.00K	—
Net Income, GAAP (USD)	$-119.95M	$-86.48M	$-69.13M	$-55.33M	$-26.29M	$-9.34M	—
Operating Cash Flow (USD)	$-95.14M	$-69.77M	$-50.14M	$-50.28M	$-23.75M	$-7.76M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters

Tyra Biosciences, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare TYRA with peers